Abstract
Cystic fibrosis has seen a multitude of therapeutic advances targeting
its downstream effects. This has led to a steady increase in survival
over the past few decades. The recent development of disease-modifying
drugs targeting the underlying CFTR mutation has revolutionized
treatment for CF. Despite these advances, individuals with CF who are
racial and ethnic minorities, from low socioeconomic status, or female
sex have worse clinical outcomes. The inequitable access to CFTR
modulators from cost and/or genetic eligibility has the potential to
further worsen the existing health disparities seen within the CF
community.